HEP PHARMA Trademark
Trademark Overview
On Thursday, June 13, 2024, a trademark application was filed for HEP PHARMA with the United States Patent and Trademark Office. The USPTO has given the HEP PHARMA trademark a serial number of 79411704. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, May 12, 2026. This trademark is owned by Shanghai HEP Biotechnology Co., Ltd. The HEP PHARMA trademark is filed in the Pharmaceutical Products category with the following description:
Medicines for Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia; pharmaceutical preparations for the prevention of Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia; chemico-pharmaceutical preparations for the prevention of Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia; biological preparations for the treatment of Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia; medical preparations for slimming purposes; slimming pills; injectable medicinal solutions, namely, pharmaceuticals for treatment of Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia; biochemical medicines for Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia
General Information
| Serial Number | 79411704 |
| Word Mark | HEP PHARMA |
| Filing Date | Thursday, June 13, 2024 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Tuesday, May 12, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Description of Mark | The mark consists of "HEP PHARMA". |
| Goods and Services | Medicines for Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia; pharmaceutical preparations for the prevention of Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia; chemico-pharmaceutical preparations for the prevention of Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia; biological preparations for the treatment of Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia; medical preparations for slimming purposes; slimming pills; injectable medicinal solutions, namely, pharmaceuticals for treatment of Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia; biochemical medicines for Hepatitis B, diabetes, non-alcoholic fatty liver disease, and hyperlipidemia |
| NOT AVAILABLE | "PHARMA" |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, December 12, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Shanghai HEP Biotechnology Co., Ltd |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | CN |
Trademark Events
| Event Date | Event Description |
| Thursday, December 12, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, December 13, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, December 13, 2024 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, December 18, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, December 24, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, December 25, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, January 22, 2025 | REFUSAL PROCESSED BY MPU |
| Wednesday, January 22, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Sunday, February 9, 2025 | REFUSAL PROCESSED BY IB |
| Friday, July 18, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, July 18, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, July 18, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, November 12, 2025 | NON-FINAL ACTION WRITTEN |
| Wednesday, November 12, 2025 | NON-FINAL ACTION E-MAILED |
| Wednesday, November 12, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, May 11, 2026 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Monday, May 11, 2026 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Tuesday, May 12, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, May 12, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, May 12, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, May 28, 2026 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
